Timothy Wyant

1.6k total citations
38 papers, 1.3k citations indexed

About

Timothy Wyant is a scholar working on Immunology, Molecular Biology and Oncology. According to data from OpenAlex, Timothy Wyant has authored 38 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Immunology, 12 papers in Molecular Biology and 10 papers in Oncology. Recurrent topics in Timothy Wyant's work include Monoclonal and Polyclonal Antibodies Research (8 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Immunotherapy and Immune Responses (7 papers). Timothy Wyant is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (8 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Immunotherapy and Immune Responses (7 papers). Timothy Wyant collaborates with scholars based in United States, Australia and Canada. Timothy Wyant's co-authors include Marcelo B. Sztein, Michael K. Tanner, Maria Rosario, Carol O. Tacket, Myron M. Levine, Irving H. Fox, Brian G. Feagan, Lili Yang, William L. Trepicchio and A. Parikh and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and The Journal of Immunology.

In The Last Decade

Timothy Wyant

35 papers receiving 1.2k citations

Peers

Countries citing papers authored by Timothy Wyant

Since Specialization

Citations

This map shows the geographic impact of Timothy Wyant's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Timothy Wyant with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Timothy Wyant more than expected).

Fields of papers citing papers by Timothy Wyant

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Timothy Wyant. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Timothy Wyant. The network helps show where Timothy Wyant may publish in the future.

Co-authorship network of co-authors of Timothy Wyant

This figure shows the co-authorship network connecting the top 25 collaborators of Timothy Wyant. A scholar is included among the top collaborators of Timothy Wyant based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Timothy Wyant. Timothy Wyant is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	464 (PB452): Determination of the phase 2 dose of AU-007, an AI-designed human monoclonal antibody that redirects IL-2 to T-effector cells 2024 ·European Journal of Cancer ·Timothy Wyant, (unknown), Drew Rasco, Andrew Haydon, John D. Powderly, Andrew Weickhardt, (unknown), Paul de Souza, Vinod Ganju, Siwen Hu‐Lieskovan, Ganessan Kichenadasse, Jiaqi Tang, Louise Richards, (unknown), Ido Amit, Yishai Ofran, Jim Vasselli	0
2	Updated results of a phase 1/2 study of AU-007, a monoclonal antibody (mAb) that binds to IL-2 and inhibits CD25 binding, in patients with advanced solid tumors. 2024 ·Journal of Clinical Oncology ·Drew Rasco, Meredith McKean, Andrew Haydon, Andrew Weickhardt, Sophia Frentzas, Elizabeth Ahern, John D. Powderly, Timothy Wyant, Jenny Tang, (unknown), (unknown), (unknown), Yanay Ofran, James R. Vasselli	1
3	Abstract C033: Preliminary pharmacodynamic evaluation of AU-007 in phase 1 dose escalation trial in patients with advanced solid tumors 2023 ·Molecular Cancer Therapeutics ·Timothy Wyant, Sophia Frentzas, Elizabeth Ahern, Andrew Weickhardt, Andrew Haydon, John D. Powderly, Drew Rasco, Meredith McKean, Paul de Souza, Jenny Tang, (unknown), (unknown), Yanay Ofran, (unknown), James R. Vasselli	1
4	Negative Feedback Expansion of Tregs Caused by Endogenous IL-2 Limits the Activity of IL-2-based Therapies 2023 ·(unknown), (unknown), (unknown), (unknown), Timothy Wyant, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Sharon Fischman, Guy Nimrod, (unknown), (unknown), James R. Vasselli, (unknown), Ronald Herbst, Yanay Ofran	5
5	Comparison of the ELISA and ECL Assay for Vedolizumab Anti-drug Antibodies: Assessing the Impact on Pharmacokinetics and Safety Outcomes of the Phase 3 GEMINI Trials 2020 ·The AAPS Journal ·Timothy Wyant, Lili Yang, Maria Rosario	19
6	CA-170, a first in class oral small molecule dual inhibitor of immune checkpoints PD-L1 and VISTA, demonstrates tumor growth inhibition in pre-clinical models and promotes T cell activation in Phase 1 study 2017 ·Annals of Oncology ·John D. Powderly, Manish R. Patel, Jina Lee, Joshua Brody, Funda Meric‐Bernstam, Erika Hamilton, Santiago Ponce Aix, Javier García-Corbacho, Y-J. Bang, M-J. Ahn, Sun Young Rha, Kwang Pyo Kim, Marta Gil-Martín, (unknown), Adam S. Lazorchak, Timothy Wyant, Anna Ma, Shefali Agarwal, David Tuck, Adil Daud	45
7	Consistent expression of guanylyl cyclase-C in primary and metastatic gastrointestinal cancers 2017 ·PLoS ONE ·Hadi Danaee, Thea Kalebic, Timothy Wyant, Matteo Fassan, Claudia Mescoli, Feng Gao, William L. Trepicchio, Massimo Rugge	27
8	Abstract A36: CA-170, an oral small molecule PD-L1 and VISTA immune checkpoint antagonist, promotes T cell immune activation and inhibits tumor growth in pre-clinical models of cancer 2017 ·Cancer Immunology Research ·Adam S. Lazorchak, (unknown), (unknown), Pottayil G. Sasikumar, (unknown), (unknown), Raghuveer Ramachandra, (unknown), Sanjeev Giri, (unknown), Murali Ramachandra, David Tuck, Timothy Wyant	9
9	Vedolizumab Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability Following Administration of a Single, Ascending, Intravenous Dose to Healthy Volunteers 2016 ·Clinical Drug Investigation ·Maria Rosario, Timothy Wyant, Timothy Leach, Serap Sankoh, Catherine Scholz, Asit Parikh, Irving H. Fox, Brian G. Feagan	38
10	DOP042. Clinical response and remission with vedolizumab across a range of baseline fecal calprotectin levels in ulcerative colitis: Results from GEMINI 1 2015 ·Journal of Crohn s and Colitis ·Walter Reinisch, James D. Lewis, Themistocles Dassopoulos, Philip Ginsburg, B E Sands, Brian G. Feagan, Silvio Danese, Arne Røseth, Maria Rosario, Huyuan Yang, A. Parikh, Brian Bressler, Timothy Wyant	2
11	Recommendations for Adaptation and Validation of Commercial Kits for Biomarker Quantification in Drug Development 2015 ·Bioanalysis ·(unknown), Ronald R. Bowsher, Mark J. Cameron, Viswanath Devanarayan, Steve Keller, Lindsay King, Jean Lee, Alyssa Morimoto, Paul Rhyne, (unknown), Yuling Wu, Timothy Wyant, D. Richard Lachno	19
12	Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease 2015 ·Alimentary Pharmacology & Therapeutics ·Maria Rosario, Nathanael L. Dirks, Marc R. Gastonguay, Adedigbo A. Fasanmade, Timothy Wyant, A. Parikh, William J. Sandborn, Brian G. Feagan, Walter Reinisch, Irving H. Fox	202
13	Validation of a flow cytometry based G2M delay cell cycle assay for use in evaluating the pharmacodynamic response to Aurora A inhibition 2010 ·Journal of Immunological Methods ·Jose Estevam, Hadi Danaee, Ray Liu, Jeffrey Ecsedy, William L. Trepicchio, Timothy Wyant	12
14	Validation of a flow cytometry based chemokine internalization assay for use in evaluating the pharmacodynamic response to a receptor antagonist 2008 ·Journal of Translational Medicine ·Timothy Wyant, (unknown), Marie Green	13
15	Modulation of CCR2 in rheumatoid arthritis: A double‐blind, randomized, placebo‐controlled clinical trial 2008 ·Arthritis & Rheumatism ·Clarissa E. Vergunst, Daniëlle M. Gerlag, (unknown), Lars Klareskog, Malcolm Smith, Filip Van den Bosch, Huib J. Dinant, Yih Lee, Timothy Wyant, Eric Jacobson, Dominique Baeten, Paul P. Tak	178
16	Concomitant Induction of CD4+ and CD8+ T Cell Responses in Volunteers Immunized with Salmonella enterica Serovar Typhi Strain CVD 908-htrA 2003 ·The Journal of Immunology ·Rosângela Salerno-Gonçalves, Timothy Wyant, Marcela F. Pasetti, Marcelo Fernández-Viña, Carol O. Tacket, Myron M. Levine, Marcelo B. Sztein	79
17	Safety and Immune Responses to Attenuated Salmonella enterica Serovar Typhi Oral Live Vector Vaccines Expressing Tetanus Toxin Fragment C 2000 ·Clinical Immunology ·Carol O. Tacket, James E. Galen, Marcelo B. Sztein, Genevieve A. Losonsky, Timothy Wyant, James P. Nataro, Steven S. Wasserman, Robert Edelman, (unknown), Gordon Dougan, Myron M. Levine	61
18	Potent Immunoregulatory Effects ofSalmonella typhiFlagella on Antigenic Stimulation of Human Peripheral Blood Mononuclear Cells 1999 ·Infection and Immunity ·Timothy Wyant, Michael K. Tanner, Marcelo B. Sztein	53
19	Investigation of trends in flooding in the Tug Fork basin of Kentucky, Virginia, and West Virginia 1982 ·Antarctica A Keystone in a Changing World ·Robert M. Hirsch, (unknown), Timothy Wyant	5
20	The oilspill risk analysis model of the U. S. Geological Survey 1980 ·Antarctica A Keystone in a Changing World ·(unknown), James Richard Slack, Timothy Wyant, (unknown)	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact